Quest Magazine

Disrupted Disease Process

A compound that has the potential to be refined and modified into a treatment for type 1 myotonic dystrophy (MMD1, or DM1) has been identified by researchers at the University of Oregon in Eugene, and the University of Rochester (N.Y.) School of Medicine and Dentistry.

MMD Research: Disrupted Disease Process

 

A compound that has the potential to be refined and modified into a treatment for type 1 myotonic dystrophy (MMD1, or DM1) has been identified by researchers at the University of Oregon in Eugene, and the University of Rochester (N.Y.) School of Medicine and Dentistry.

New Mattie Book

 MDA National Vice President Jeni Stepanek will be a guest on the November 2 broadcast of ABC's "Good Morning America" to promote the release of Messenger: The Legacy of Mattie J. T. Stepanek and Heartsongs, an inside look at the life of her famous son, who served as MDA’s National Goodwill Ambassador from 2002-2004.

ALS Research: MDA Hosts 'Think Tank'

 

An all-day "think tank" to consider priorities for amyotrophic lateral sclerosis (ALS) research based on the latest information was conducted with ten of the leading scientists and clinicians in the field and senior MDA staff in Tucson, Ariz., on Saturday, Oct. 24, 2009.

Each specialist introduced his or her area of expertise and led an approximately 20-minute discussion, gathering input and answering questions from the other participants.

Vote Abbey for Gap Kid!

Abbey Umali needs your vote.

The vivacious 10-year-old, who is MDA’s National Goodwill Ambassador, is competing for the chance to add another title to her resume: Gap Kid.

Popular international retailer Gap has launched a nationwide search for the next faces for GapKids, its kids’ clothing line. Abbey, who has a form of Charcot-Marie-Tooth disease, is in the running and could use your help to win "fan favorite."

ALS Research: APC & ALS

A compound known as "activated protein C" (APC) that is already in use to treat severe bloodstream infections also may have benefit in ALS, according to a recently published report.

ALS Research: APC & ALS

A compound known as "activated protein C" (APC) that is already in use to treat severe bloodstream infections also may have benefit in ALS, according to a recently published report.

MDA Hosts One-Day ALS 'Think Tank'

Neurologist Valerie Cwik, senior executive vice president-research and medical director at MDA, and neurologist Stan Appel

DMD Research: US Exon Skipping Trial

The first human trial in the United States of a treatment strategy known as "exon skipping" for Duchenne muscular dystrophy (DMD) is scheduled to begin in March 2010 at Nationwide Children's Hospital in Columbus, Ohio, one of five elite centers comprising MDA's DMD Clinical Research Network.

First Human Exon Skipping Trial in US Planned for 2010

Pages